TRAJENTA® is backed by one of the most unique and robust CVOT programmes across a broad range of T2D patients.
- 6,979 patients at high risk for
heart disease and/or CKD‡
- TRAJENTA® vs placebo
- 2.2 years median follow-up
- 6,033 relatively early T2D
patients at increased CV risk§
- TRAJENTA® vs glimepiride
- 6.3 years median follow-up
*The CARMELINA® primary endpoint is time to first occurrence of any of the following components: CV death, non-fatal MI, non-fatal stroke. The key secondary endpoint is time to first occurrence of any of the following components: death due to kidney disease, sustained ESRD or a sustained decrease of ≥40% in eGFR from baseline.
†The CAROLINA® primary endpoint is time to first occurrence of any of the following components: CV death, non-fatal MI and non-fatal stroke.
‡CARMELINA® included patients with albuminuria & previous macrovascular disease, and/or impaired kidney function with or without CV comorbidities.
§CAROLINA® included patients with early type 2 diabetes and at increased CV risk
CKD: Chronic kidney disease; CV: Cardiovascular; CVOT: Cardiovascular outcome trial; eGFR: Estimated glomerular filtration rate; ESRD: End-stage renal disease; MI: Myocardial infarction.